Linked e-resources
Details
Table of Contents
Intro; "Resistance to Targeted Anti-Cancer Therapeutics": Aims and Scope; Preface; Biography of Series Editor; Acknowledgments; Contents; Clinical Use and Efficacy of Ibritumomab in B Cell Lymphoma; 1 Introduction; 2 Characteristics of Zevalin; 3 Treatment Schedule and Dosage of Zevalin; 4 Patient Eligibility; 5 Zevalin in Relapse or Refractory Patients; 6 Zevalin in Frontline Therapy; 7 Toxicities and Safety Profile; 8 Factor Associated with Effects of Zevalin; 9 Future Aspects; References; Biology and Pathology of B-Cell Lymphoma; 1 Introduction; 2 Cellular Origin of B-Cell Lymphomas.
3 Features of Ibritumomab4 A Model of Theranostic Approach; 5 Enhancing Efficacy of Ibritumomab Tiuxetan; 6 Conclusion; References; Radiological Evaluation of Response and Resistance of Ibritumomab; 1 Introduction; 2 Evaluation of FDG-PET/CT for Monitoring the Response to RIT; 2.1 FDG-PET/CT Imaging; 3 Summary of the Results; 4 Discussion; 5 Conclusions; References; Characteristics of Ibritumomab as Radionuclide Therapy Agent; 1 Introduction; 2 CD 20: B-Cell Antigen; 3 mAb Targeting CD20; 4 Ibritumomab Tiuxetan Coupled with Radioisotopes; 4.1 Ibritumomab; 4.2 Tiuxetan; 4.3 Radionuclides.
5 Yttrium-90 (90Y)6 Indium-111 (111In); 7 Preclinical Investigation of 90Y-/111In-Ibritumomab Tiuxetan; 7.1 In Vitro Studies; 7.2 Ex Vivo/In Vivo Studies; 8 Imaging and Therapy Protocol; 8.1 Preparation of 90Y-Ibritumomab Tiuxetan; 8.2 Schedule of 90Y-Ibritumomab Tiuxetan Therapy; 9 Perspectives and Conclusion; References; Resistance and Heterogeneity of Intratumoral Antibody Distribution; 1 Introduction; 2 SPECT/CT and PET/CT System; 3 Statistical Approach Taken to Characterize Lesion's Uptake; 4 Resistance and Heterogeneity of Intratumoral Antibody Distribution.
5 Conclusions and PerspectivesReferences; Radiation Dosimetry in Ibritumomab Therapy; 1 Introduction; 2 Activity Escalation Trial and Dose Escalation Trial; 3 Dosimetry for Molecular Radiotherapy; 3.1 Quantification of Pharmacokinetics; 3.2 Kinetic Model; 3.3 Prediction of Pharmacokinetics During Therapy; 3.4 Absorbed Dose Calculations; 3.5 Treatment Planning; 3.6 Treatment and Quality Control Measurements; 3.7 Conclusion; 4 Dosimetry for Ibritumomab Tiuxetan; 5 Treatment Planning for [90Y]Ibritumomab Tiuxetan; 6 Conclusion and Outlook; References.
3 Features of Ibritumomab4 A Model of Theranostic Approach; 5 Enhancing Efficacy of Ibritumomab Tiuxetan; 6 Conclusion; References; Radiological Evaluation of Response and Resistance of Ibritumomab; 1 Introduction; 2 Evaluation of FDG-PET/CT for Monitoring the Response to RIT; 2.1 FDG-PET/CT Imaging; 3 Summary of the Results; 4 Discussion; 5 Conclusions; References; Characteristics of Ibritumomab as Radionuclide Therapy Agent; 1 Introduction; 2 CD 20: B-Cell Antigen; 3 mAb Targeting CD20; 4 Ibritumomab Tiuxetan Coupled with Radioisotopes; 4.1 Ibritumomab; 4.2 Tiuxetan; 4.3 Radionuclides.
5 Yttrium-90 (90Y)6 Indium-111 (111In); 7 Preclinical Investigation of 90Y-/111In-Ibritumomab Tiuxetan; 7.1 In Vitro Studies; 7.2 Ex Vivo/In Vivo Studies; 8 Imaging and Therapy Protocol; 8.1 Preparation of 90Y-Ibritumomab Tiuxetan; 8.2 Schedule of 90Y-Ibritumomab Tiuxetan Therapy; 9 Perspectives and Conclusion; References; Resistance and Heterogeneity of Intratumoral Antibody Distribution; 1 Introduction; 2 SPECT/CT and PET/CT System; 3 Statistical Approach Taken to Characterize Lesion's Uptake; 4 Resistance and Heterogeneity of Intratumoral Antibody Distribution.
5 Conclusions and PerspectivesReferences; Radiation Dosimetry in Ibritumomab Therapy; 1 Introduction; 2 Activity Escalation Trial and Dose Escalation Trial; 3 Dosimetry for Molecular Radiotherapy; 3.1 Quantification of Pharmacokinetics; 3.2 Kinetic Model; 3.3 Prediction of Pharmacokinetics During Therapy; 3.4 Absorbed Dose Calculations; 3.5 Treatment Planning; 3.6 Treatment and Quality Control Measurements; 3.7 Conclusion; 4 Dosimetry for Ibritumomab Tiuxetan; 5 Treatment Planning for [90Y]Ibritumomab Tiuxetan; 6 Conclusion and Outlook; References.